IGM Biosciences, Inc.

Equities

IGMS

US4495851085

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
9.4 ^USD	+22.88%		+30.56%	+13.12%

Apr. 17	IGM Biosciences, Sanofi Narrow Partnership to Focus on Potential Immunology and Inflamation Targets	MT
Apr. 17	IGM Biosciences, Inc. Announces Refocusing of Sanofi Collaboration	CI

IGM Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 07, 2024 at 04:06 pm EST

IGM Biosciences, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 246.42 million compared to USD 221.1 million a year ago. Basic loss per share from continuing operations was USD 4.71 compared to USD 5.32 a year ago.

Latest news about IGM Biosciences, Inc.

IGM Biosciences, Sanofi Narrow Partnership to Focus on Potential Immunology and Inflamation Targets	Apr. 17	MT
IGM Biosciences, Inc. Announces Refocusing of Sanofi Collaboration	Apr. 17	CI
North American Morning Briefing : Stocks Set for -2-	Mar. 28	DJ
HC Wainwright Adjusts IGM Biosciences Price Target to $12 From $7, Maintains Neutral Rating	Mar. 12	MT
Earnings Flash (IGMS) IGM BIOSCIENCES Reports Q4 Revenue $651,000	Mar. 07	MT
IGM Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 07	CI
IGM Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
North American Morning Briefing : Stock Futures -2-	Feb. 12	DJ
RBC Upgrades IGM Biosciences to Outperform From Sector Perform, Boosts Price Target to $21 From $9; Speculative Risk Kept	Feb. 09	MT
Transcript : IGM Biosciences, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 11:15 AM	Jan. 10
North American Morning Briefing : Stock Futures -2-	Dec. 18	DJ
BofA Securities Downgrades IGM Biosciences to Neutral From Buy, Adjusts Price Target to $8 From $20	Dec. 15	MT
IGM Biosciences, Inc.(NasdaqGS:IGMS) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
North American Morning Briefing : Futures Pause -2-	Dec. 08	DJ
HC Wainwright Downgrades IGM Biosciences to Neutral From Buy, Cuts Price Target to $7 From $11	Dec. 07	MT
Wedbush Raises IGM Biosciences' PT to $20 From $16, Adjusts Downstream Funding Assumptions; Keeps Outperform Rating	Dec. 06	MT
RBC Raises Price Target on IGM Biosciences to $9 From $8 on Reduced Ancillary Spend Amid Job Cuts, Keeps Sector Perform, Speculative Risk	Dec. 06	MT
Medivir to Discuss Birinapant Future Following Partner's Strategic Reprioritization	Dec. 06	MT
North American Morning Briefing : Stock Futures Rise With More Jobs Data on Tap	Dec. 06	DJ
IGM Biosciences to Reduce Workforce by 22%, Pause Hematologic Oncology Clinical Development	Dec. 06	MT
Igm Biosciences, Inc. to Reduce its Workforce by Approximately 22%	Dec. 05	CI
IGM Biosciences, Inc. Announces Plans to File IND for IGM-2644 (CD38 x CD3) to Treat Autoimmune Disease	Dec. 05	CI
North American Morning Briefing : Stock Futures Hold Near Two-Month Highs	Nov. 16	DJ
Morgan Stanley Adjusts IGM Biosciences Price Target to $8 From $15, Maintains Equal Weight Rating	Nov. 15	MT
HC Wainwright Adjusts Price Target on IGM Biosciences to $11 From $17, Keeps Buy Rating	Nov. 15	MT

Chart IGM Biosciences, Inc.

Duration

Period

More charts

Company Profile

IGM Biosciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing and delivering a new class of medicines to treat patients with cancer and autoimmune and inflammatory diseases. The Companyâs pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only two binding sites. It is also focused on creating, developing, manufacturing, and commercializing IgM antibody agonists against oncology and immunology and inflammation targets. The Companyâs development programs include Aplitabart, Imvotamab, and IGM-2644. Aplitabart is an IgM antibody targeting Death Receptor 5 (DR5) proteins, being evaluated in multiple phase I combination trials for the treatment of colorectal cancer. Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. IGM-2644 is a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for IGM Biosciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

9.4 USD

Average target price

21.6 USD

Spread / Average Target

+129.79%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
IGM BIOSCIENCES, INC.	+13.12%	554M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs